Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Azelastine · 1 trial · 1 indication
Evaluated by rating the following symptoms (sneezing, runny nose, itchy nose, and nasal congestion) on a scale from 0-3 (0 = None, 1= Mild symptoms, 2 = Moderate symptoms, 3 = Severe symptoms)
| Arm | Type | Description |
|---|---|---|
| Azelastine hydrochloride 0.15% + Placebo | EXPERIMENTAL | Each participant will receive a single dose (two sprays per nostril) of study intervention Azelastine hydrochloride 0.15% and Placebo at treatment period 1 and 2 respectively. |
| Placebo + Azelastine hydrochloride 0.15% | EXPERIMENTAL | Each participant will receive a single dose (two sprays per nostril) of study intervention Placebo and Azelastine hydrochloride 0.15% at treatment period 1 and 2 respectively. |
| Name | Type | Description |
|---|---|---|
| Azelastine hydrochloride (BAYR9258) | DRUG | Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration. |
| Placebo | DRUG | Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration. |
Inclusion Criteria: * Healthy, ambulatory, male or female volunteers 18 to 65 years of age with selfreported allergic rhinitis to ragweed pollen for at least 2 years prior. * Documented positive skin prick test response to common ragweed (ambrosia artemisiifolia) pollen; prick with wheal ≥3 mm larg...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | N/A | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
Azelastine is used for the treatment of Allergic Rhinitis. It is administered as a nasal spray, specifically Azelastine Hydrochloride 0.15% Nasal Spray, and is being studied to determine how quickly it relieves symptoms in patients suffering from this condition.
Azelastine is a small molecule that targets histamine receptors. As an antihistamine, it works by blocking the effects of histamine, a substance in the body that causes allergic symptoms such as sneezing, itching, and a runny nose, thereby providing relief from allergic rhinitis symptoms.
Azelastine is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is listed on the stock exchange under the ticker symbol BAYRY.
Azelastine is currently in Phase 3 clinical development. It is an investigational drug for the treatment of Allergic Rhinitis and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed.
Azelastine is being studied in a Phase 3 clinical trial with the identifier NCT04264637. This trial, titled 'Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis,' enrolled 110 participants in Canada. The trial was randomized, double-blind, and controlled, and it has been completed.
Azelastine is the active ingredient in the medication Azelastine Hydrochloride. The drug is formulated as a nasal spray containing Azelastine Hydrochloride 0.15%, which is the specific form used in the clinical trial for Allergic Rhinitis.